Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a large drop in short interest in September. As of September 30th, there was short interest totalling 1,600 shares, a drop of 33.3% from the September 15th total of 2,400 shares. Based on an average trading volume of 27,300 shares, the days-to-cover ratio is currently 0.1 days.

Enzon Pharmaceuticals Price Performance

OTCMKTS ENZN traded down $0.01 during midday trading on Monday, hitting $0.11. 14,996 shares of the company traded hands, compared to its average volume of 24,505. The company has a market cap of $8.16 million, a PE ratio of 11.00 and a beta of 0.48. The company’s 50-day simple moving average is $0.14 and its 200-day simple moving average is $0.13. Enzon Pharmaceuticals has a 52 week low of $0.06 and a 52 week high of $0.24.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.